Patients undergoing liver surgery have long been considered to be at low risk of venous thromboembolism. However, pulmonary embolism has recently emerged as an increasingly frequent and potentially fatal complication following liver…
Category: News
Health Canada approves Microsulis Medical’s Accu2i percutaneous microwave tissue ablation system
Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that it has received approval from Health Canada for the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system…
Lifestyle more closely linked with childhood obesity, than genetics
Are some children genetically tuned to be overweight, or is lifestyle to blame for childhood obesity? Check-ups of 1,003 Michigan 6th graders in a school-based health program showed children who are obese…
Histamine can be an important molecule to develop new treatments for MS
If you think histamines are your nemesis during allergy season, here’s something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an…
Cappella initiates multi-center Italian Sideguard open label clinical study
Cappella Medical Devices announces initiation of the multi-center Italian Sideguard® open label clinical study. The Principal Investigator (PI) of the study, Dr. Giuseppe Massimo Sangiorgi at the Policlinico di Modena – University…
FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator
Mederi Therapeutics Inc. announced today that it has received FDA 510(k) clearance for its new MDRF1 Generator. The Mederi RF Generator powers the Stretta® System for treatment of Gastroesophageal Reflux Disease (GERD)…
MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults
Allergan, Inc. and MAP Pharmaceuticals, Inc. today announced a collaboration within the United States for LEVADEX™, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of…
VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety…
Baxter launches OLIMEL emulsion for parenteral nutrition
Baxter International Inc. today announced the launch of OLIMEL (Amino Acids, Dextrose and Lipids, with/without Electrolytes) emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition’s (A.S.P.E.N.) Clinical…
Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis
Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic (designated as ASP2408)…
Having facial moles ‘could mean healthier heart’
Having moles is usually a cause for embarrassment, but not any more, according to scientists. A research team from King’s College London believes that people with moles have tougher bones than normal,…
Researchers Uncover Genetic Clues To Compulsive, Self-Injurious Behavior In Rare Childhood Disorder
Research from the University of California, San Diego School of Medicine provides new clues for the compulsive behavior and cognitive defects associated with a rare childhood neurological disease called Lesch-Nyhan Disease (LND)….
Patients Need Continuing Access To Life-Saving Treatment
The American Psychiatric Association is pleased that patients will continue to have access to life-saving Electroconvulsive Therapy (ECT) following an FDA advisory panel’s two-day discussion about a possible reclassification of ECT devices….
Employing Novel Surgery To Remove Rare Tumor, Rebuild Trachea
Using a novel surgical approach, it’s possible to rebuild the trachea and preserve a patient’s voice after removing an invasive throat tumor, according to a new report from Henry Ford Hospital in…
Advaxis Science & Operations Officer Moderates Live Vaccine Panel At Cancer Drug Research Conference
Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., (OTCBB: ADXS) the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, “Live Cancer Vaccines.” Topics addressed by…